Roles for NUAK2 in several non-CNS cancers have been reported, with its expression being highly correlated with tumor progression and poor prognosis in patients (Li et al, 2021; Namiki et al, 2015, 2011; Tang et al, 2017; Wang et al, 2024; Fu et al, 2022). This evidence concerns the gene NUAK2 and central nervous system cancer.